Drug details

Defitelio (defibrotide sodium for intravenous use)

type of Thrombolytics

Defitelio (defibrotide sodium) injection is the first in its class of an oligonucleotide that acts as a polydeoxyribonucleotide adenosine receptor, with antithrombotic, anti-inflammatory, and anti-ischemic properties, indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• itching,
• skin rash,
• easy bruising,
• unusual bleeding,
• confusion,
• vision problems,
• headaches,
• lightheadedness
• blood in your urine or stools,
• slurred speech, and

The following drugs are related to Defitelio, either as a replacement or used together:

• Libtayo (cemiplimab-rwlc injection)
• Questran (cholestyramine)
• Colestid (colestipol)
• Mannitol IV (mannitol injection)
• Midazolam Injection (midazolam)
• Midazolam Hydrochloride Syrup (midazolam hcl syrup)
• Nembutal (pentobarbital)
• Pfizerpen (penicillin g potassium)